Navigation Links
Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Date:10/18/2007

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that data related to the Company's Amyotrophic Lateral Sclerosis (ALS) drug candidate, AL-02, will be presented at the 18th International Symposium on ALS/MND which will be held on December 1-3, 2007, in Toronto, Canada. The poster presentation by Allitia DiBernardo, M.D. of Massachusetts General Hospital will discuss a pooled analysis of survival data from three randomized, placebo-controlled studies. Results suggest a trend towards increased survival in patients taking AL-02.

The combined analysis examined three trials and included a total of 386 patients. The three trials were conducted by the Northeast ALS Consortium (NEALS), Carolinas Medical Center and Utrecht University. The pooled analysis showed an increase of 1.47-fold in median survival compared to results in patients taking a placebo. Certain portions of these data were presented to the FDA and formed the basis for Avicena's intent to initiate a confirmatory Phase III trial in 2008. This study will evaluate AL-02's effect on the primary endpoint of median survival and secondary endpoints of ALS functional scores.

"These data points support AL-02's positive effect on the survival rate of ALS patients," stated Belinda Tsao-Nivaggioli, Chairman and C.E.O. of Avicena. "We are very encouraged by these results and we will continue to advance AL-02 towards commercialization, as well as our drug candidates for Parkinson's and Huntington's disease. AL-02 will be the Company's third late-stage drug candidate."

ABOUT ALS

ALS is a neurodegenerative disease that attacks the motor neurons of the brain and spinal cord that are responsible for voluntary muscle movement. As these motor neurons degenerate, their ability to send impulses to the muscle fibers is c
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 New-generation ... being highly portable and lightweight. Simultaneously, circuitry is ... the processing speed to which it performs at. ... medical electronics and military equipment, such as cameras ... Omnetics, micro-circular and nano-circular connectors include custom cable ...
(Date:6/18/2013)... CAMPBELL, Calif. , June 18, 2013 /PRNewswire/ ... company focused on the development of next-generation atrial ... Patent No. 8295902 by the US Patent and ... patent encompasses low profile electrode assemblies for use ... endovascular ablation or other surgical procedures. ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
(Date:6/18/2013)... Destin, FL (PRWEB) June 18, 2013 ... coast by storm. The burgeoning aquaculture industry is redefining ... Jekyll, one of the most acclaimed personal culinary chefs ... his clientele on benefits of sustainable seafood and the ... used in abundance these days. Many consumers strive to ...
(Date:6/18/2013)... As Mirena lawsuit claims continue to ... report has revealed that that the IUD has been the ... (FDA) adverse event reports since coming on the market in ... Mirena users have reported device dislocation or migration to the ... uterine perforations due to Mirena.* , “We are not at ...
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 New York ... Center to its “Best Doctors” list, up from 129 ... York City. The new issue also lists 52 additional doctors ... continues on a strategic growth trajectory. The “Best Doctors” issue, ... in the June 24 print issue and is available online ...
(Date:6/18/2013)... -- Lauren Sciences, a privately-held biotechnology company furthering ... announced today that it was independently recognized as ... V-Smart Platform, and selected as a Featured Company, ... , The report, " Early Stage Drug ... ," features companies MCD Group independently selected as ...
(Date:6/18/2013)... People with HIV are more likely to keep their ... if they feel their physician listens, explains things ... a "case," new Johns Hopkins research suggests. , "If ... to them, they feel that doctor has their best ... follow medical advice," says study leader Tabor E. Flickinger, ...
Breaking Medicine News(10 mins):Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2
... for white bread pause to hear this. New reports show ... white bread could lead to cancer of the kidneys. // ... come to conclusion that use of excessive refined flour in ... which in turn stimulates the release of insulin into the ...
... as a magic bullet for obesity — rimonabant (Acomplia) — ... and also helps lower cardiac risk factors, according to a ... Europe in July, and U.S. approval is pending before the ... way, suppressing the appetite by targeting the brain cells involved ...
... and Mentor Corp. breast implant makers on Friday said that ... silicone gel breast implants back on the market. // ... Health Canada has granted the company a license for sale ... well as Style 410 Shaped and Textured implants. Earlier this ...
... been formally launched by the Chief Minister Y. S. ... temple area of Pardiwada in Maharajgunj constituency here. // ... impetus on the phasing out of the dustbin system ... supplied with small plastic bins. Garbage collectors on cycle ...
... Virginia University professor and two alumni have tracked the ... the eye and often leads to blindness and death.// ... treatment for those who suffer from it. ,Joginder ... doctoral students Jason White ('02) and Alison Director-Myska ('96) ...
... the gut has been found to be an effective ... researchers at Cedars-Sinai Medical Center. ,The study ... the Annals of Internal Medicine It is the ... end of the course of treatment has ended. This ...
Cached Medicine News:Health News:Latest Weight-Loss Pill Offers Modest Results, Blocks 'Munchies' 2Health News:Latest Weight-Loss Pill Offers Modest Results, Blocks 'Munchies' 3Health News:YSR launches 'Operation Dengue' 2Health News:Team Tracks Genetic Origins of Eye Cancer 2Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... A1c-Cellular is the first HbA1c control available ... the entire HbA1c procedure including the lysing ... is a ready-to-use liquid control with an ... closed-vial stability of six months when refrigerated. ...
...
Medicine Products: